Emily Katherine Ackerman, MD
Psychiatry · Panorama City
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
- Since medical school
- 11 years
- University of California, Irvine, California College of Medicine, 2015
Offices
2 locations · Innovative Medical Solutions Inc A Medical Group · Clarity-James Medical Services Corp
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Ackerman’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A146938 · Current
Licensed to practise in California · since 2017 · expires 2028-05-31 · University of California, Irvine College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Psychiatry and Neurology - Psychiatry
Original Medicare doctor bills
$16,175
Medicare paid this office $16,175 for 37 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 16 | $9,831 | $97 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $1,857 | $133 |
| New patient visit (45+ min) | 12 | $1,423 | $119 |
| Hospital discharge day management, 30 minutes or less | 13 | $948 | $68 |
Who their Medicare patients are
37 Original Medicare patients in 2024. Average age 58 · Under 65 57% · Women 46% · Also on Medicaid 68% · Health risk score 1.38. Above the middle of the specialty; the typical psychiatry clinician is at 1.35.
Conditions among them: High blood pressure 65% · Depression 62% · Diabetes 30%.
The office billed $41,676, Medicare allowed $20,605 and paid $16,175; for 174 services of 9 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 37 | 174 | 58 | 1.38 | $41,676 | $16,175 |
| 2023 | 53 | 277 | 50 | 1.54 | $65,230 | $26,745 |
| 2022 | 119 | 510 | 47 | 1.31 | $119,150 | $44,553 |
| 2021 | 73 | 316 | 45 | 1.34 | $54,518 | $26,937 |
| 2020 | 17 | 87 | 51 | 1.45 | $9,151 | $6,431 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 3 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 42 | $19,408 | $99 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 25 | $4,214 | $136 |
| Hospital discharge day management, 30 minutes or less | 22 | $1,539 | $67 |
2022: 3 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 99 | $31,842 | $86 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 49 | $8,555 | $153 |
| Hospital discharge day management, 30 minutes or less | 34 | $2,148 | $61 |
2021: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 51 | $13,696 | $87 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 29 | $4,757 | $159 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $4,103 | $60 |
| Hospital discharge day management, 30 minutes or less | 18 | $1,059 | $59 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 12 | $459 | $33 |
2020: 2 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $2,609 | $62 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 12 | $1,553 | $119 |
Medicaid work
$905 in 2023
Medicaid paid $905 for 30 billed services this clinician did in 2023, up to 14 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 30 | $905 |
| 2023 | 30 | 1 | 14 | $905 |
| 2022 | 47 | 1 | 15 | $808 |
See the largest Medicaid services in earlier years
2022
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 47 | $808 |
Drugs they prescribed that Part D paid
$19,127
Pharmacies billed $19,127 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 443) in 2024. At or below the middle of the specialty; the typical psychiatry clinician is at 0%.
437 generic and fewer than 11 brand-name prescriptions · $19,127 in drug cost · 51 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Lurasidone | 12 | $8,519 | $710 |
| Bupropion Xl | 35 | $2,117 | $60 |
| Duloxetine | 26 | $1,058 | $41 |
| Prazosin | 17 | $362 | $21 |
| Aripiprazole | 24 | $357 | $15 |
See all 13 drugs
| Lurasidone | 12 | $8,519 | $710 |
| Bupropion Xl | 35 | $2,117 | $60 |
| Duloxetine | 26 | $1,058 | $41 |
| Prazosin | 17 | $362 | $21 |
| Aripiprazole | 24 | $357 | $15 |
| Divalproex | 18 | $237 | $13 |
| Olanzapine | 22 | $231 | $11 |
| Escitalopram | 23 | $149 | $6 |
| Trazodone | 12 | $143 | $12 |
| Quetiapine | 47 | $140 | $3 |
| Buspirone | 14 | $128 | $9 |
| Sertraline | 15 | $58 | $4 |
| Clonazepam | 14 | $43 | $3 |
Year by year
| 2024 | 443 | 73 | 0% (0) | None | $19,127 |
| 2023 | 648 | 107 | 0% (0) | 3% | $36,129 |
| 2022 | 1,401 | 116 | 0% (0) | 4% | $126,809 |
| 2021 | 788 | 113 | 0% (0) | 4% | $61,794 |
| 2020 | 85 | 23 | 0% (0) | None | $7,109 |
| 2019 | 69 | None | 0% (0) | None | $10,400 |
| 2018 | 101 | None | 0% (0) | 12% | $8,766 |
| 2017 | 107 | None | 0% (0) | None | $4,885 |
| 2016 | 13 | None | 0% (0) | 0% | $518 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 21 drugs
| Lurasidone | 12 | $4,426 | $369 |
| Bupropion Xl | 46 | $3,496 | $76 |
| Quetiapine Fumarate Er | 11 | $1,684 | $153 |
| Quetiapine | 69 | $1,309 | $19 |
| Aripiprazole | 27 | $1,018 | $38 |
| Ziprasidone | 15 | $707 | $47 |
| Divalproex | 17 | $529 | $31 |
| Olanzapine | 30 | $465 | $16 |
| Trazodone | 24 | $406 | $17 |
| Lamotrigine | 35 | $406 | $12 |
| Duloxetine | 14 | $396 | $28 |
| Buspirone | 18 | $314 | $17 |
| Venlafaxine Hcl Er | 18 | $304 | $17 |
| Sertraline | 32 | $235 | $7 |
| Risperidone | 14 | $231 | $17 |
| Alprazolam | 20 | $221 | $11 |
| Escitalopram | 33 | $201 | $6 |
| Gabapentin | 18 | $191 | $11 |
| Diazepam | 12 | $159 | $13 |
| Lorazepam | 18 | $132 | $7 |
| Clonazepam | 17 | $105 | $6 |
2022: 33 drugs
| Abilify Maintena | 12 | $30,695 | $2,558 |
| Latuda | 20 | $30,292 | $1,515 |
| Aripiprazole | 31 | $3,073 | $99 |
| Bupropion Xl | 65 | $2,193 | $34 |
| Doxepin | 12 | $1,977 | $165 |
| Quetiapine | 84 | $1,548 | $18 |
| Duloxetine | 55 | $1,340 | $24 |
| Trazodone | 79 | $1,031 | $13 |
| Buspirone | 52 | $983 | $19 |
| Lamotrigine | 95 | $896 | $9 |
| Olanzapine | 33 | $885 | $27 |
| Quetiapine Fumarate Er | 24 | $836 | $35 |
| Venlafaxine Hcl Er | 59 | $828 | $14 |
| Ziprasidone | 14 | $818 | $58 |
| Sertraline | 91 | $806 | $9 |
| Escitalopram | 95 | $674 | $7 |
| Divalproex Sodium Er | 19 | $664 | $35 |
| Gabapentin | 54 | $654 | $12 |
| Nortriptyline | 31 | $597 | $19 |
| Clozapine | 15 | $510 | $34 |
| Mirtazapine | 41 | $446 | $11 |
| Divalproex | 29 | $388 | $13 |
| Clonazepam | 41 | $245 | $6 |
| Fluoxetine | 48 | $244 | $5 |
| Lithium Carbonate Er | 13 | $207 | $16 |
| Hydroxyzine Pamoate | 18 | $157 | $9 |
| Lorazepam | 53 | $143 | $3 |
| Alprazolam | 18 | $127 | $7 |
| Benztropine Mesylate | 13 | $121 | $9 |
| Propranolol | 13 | $99 | $8 |
| Dextroamphetamine-Amphetamine | 12 | $93 | $8 |
| Citalopram Hbr | 11 | $81 | $7 |
| Diazepam | 12 | $23 | $2 |
2021: 21 drugs
| Ramelteon | 14 | $2,801 | $200 |
| Aripiprazole | 21 | $1,133 | $54 |
| Quetiapine | 48 | $1,090 | $23 |
| Duloxetine | 39 | $875 | $22 |
| Buspirone | 41 | $754 | $18 |
| Doxepin | 12 | $741 | $62 |
| Bupropion Xl | 30 | $667 | $22 |
| Escitalopram | 55 | $441 | $8 |
| Sertraline | 51 | $435 | $9 |
| Olanzapine | 20 | $386 | $19 |
| Lamotrigine | 34 | $356 | $10 |
| Hydroxyzine | 16 | $289 | $18 |
| Gabapentin | 29 | $269 | $9 |
| Venlafaxine Hcl Er | 19 | $209 | $11 |
| Fluoxetine | 37 | $168 | $5 |
| Benztropine Mesylate | 16 | $144 | $9 |
| Mirtazapine | 17 | $143 | $8 |
| Trazodone | 17 | $140 | $8 |
| Alprazolam | 17 | $132 | $8 |
| Nortriptyline | 11 | $124 | $11 |
| Lorazepam | 14 | $54 | $4 |
2019: 1 drug
| Prazosin | 13 | $729 | $56 |
2018: 5 drugs
| Venlafaxine Hcl Er | 12 | $4,074 | $339 |
| Fluphenazine | 15 | $2,583 | $172 |
| Clozapine | 12 | $708 | $59 |
| Trihexyphenidyl | 15 | $113 | $8 |
| Divalproex | 12 | $73 | $6 |
2017: 3 drugs
| Divalproex Sodium Er | 19 | $971 | $51 |
| Prazosin | 16 | $722 | $45 |
| Divalproex | 11 | $74 | $7 |
Money from drug and device companies
$84 in 2025
| 2025 | 2 | 2 | None | $84 |
| 2024 | 10 | 24 | None | $618 |
| 2023 | 8 | 20 | None | $509 |
| 2022 | 4 | 14 | None | $263 |
| 2021 | 7 | 12 | None | $246 |
| 2020 | 7 | 16 | None | $321 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Merck Sharp & Dohme | None | $61 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | None | $23 | 1 payment
|
See all 2 published payments
| Merck Sharp & Dohme | Meals · 2025-10-27 | None | $61 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-01-03 | None | $23 |
See earlier years (2024, 2023, 2022, 2021, 2020)
2024: $618
| ViiV Healthcare | Dovato | $187 | 8 payments
|
| Vanda Pharmaceuticals | Hetlioz | $108 | 3 payments
|
| Janssen Pharmaceuticals | Invega Sustenna | $72 | 3 payments
|
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Caplyta | $59 | 2 payments
|
| Abbvie | Vraylar | $47 | 2 payments
|
| Neurocrine Biosciences | Ingrezza | $31 | 1 payment
|
| Lundbeck | Rexulti | $31 | 2 payments
|
| Alkermes | Aristada | $30 | 1 payment
|
| Almatica Pharma | Loreev Xr | $27 | 1 payment
|
| Teva Pharmaceuticals USA | Austedo Xr | $26 | 1 payment
|
2023: $509
| Vanda Pharmaceuticals | Hetlioz | $187 | 6 payments
|
| AbbVie | Vraylar | $92 | 4 payments
|
| Janssen Pharmaceuticals | Invega Sustenna | $76 | 3 payments
|
| Teva Pharmaceuticals USA | Uzedy | $53 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Trintellix | $42 | 2 payments
|
| Indivior | Perseris | $25 | 1 payment
|
| OWP Pharmaceuticals | Subvenite | $21 | 1 payment
|
| Idorsia Pharmaceuticals US | Quviviq | $13 | 1 payment
|
2022: $263
| Abbvie | Vraylar | $122 | 8 payments
|
| Teva Pharmaceuticals USA | Austedo | $83 | 4 payments
|
| Vanda Pharmaceuticals | Hetlioz | $34 | 1 payment
|
| Alkermes | Aristada | $23 | 1 payment
|
2021: $246
| Janssen Pharmaceuticals | Invega Sustenna | $75 | 3 payments
|
| Iti | Caplyta | $60 | 3 payments
|
| Vanda Pharmaceuticals | Hetlioz | $29 | 1 payment
|
| Sunovion Pharmaceuticals | Latuda | $23 | 2 payments
|
| Teva Pharmaceuticals USA | Austedo | $21 | 1 payment
|
| Bausch Health US | Aplenzin | $20 | 1 payment
|
| Lundbeck | Brintellix | $17 | 1 payment
|
2020: $321
| Alkermes | Aristada | $134 | 6 payments
|
| Janssen Pharmaceuticals | Invega Sustenna | $99 | 4 payments
|
| Vanda Pharmaceuticals | Hetlioz | $25 | 2 payments
|
| Adlon Therapeutics L.P. | Adhansia Xr | $22 | 1 payment
|
| Indivior | Perseris | $16 | 1 payment
|
| Bausch Health US | Wellbutrin | $14 | 1 payment
|
| Avanir Pharmaceuticals | Nuedexta | $11 | 1 payment
|
Professional record
- NPI
- 1861887945
- Licence
- CA A146938California A146938: Current · expires 2028-05-31
- Trained
- University of California, Irvine, California College of Medicine, 2015 · 11 years ago
- Group
- Innovative Medical Solutions Inc A Medical Group · Clarity-James Medical Services Corp
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Psychiatry (2084P0800X)
- Mailing address
- Po Box 1770, La Mesa, CA, 91944
- NPI first listed
- 2015-04-05
- NPI last updated
- 2025-04-11
- NPI record certified
- 2025-04-11
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 415 W Route 66 Ste 202, Glendora, CA, 91740